Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata, the FDA issued a Warning Letter to Shriram Institute for Industrial Research on April 15, 2020, regarding drug manufacturing or compliance issues. While the specific violations cannot be detailed without access to the full letter text, the warning indicates the company failed to meet FDA standards for drug products under federal regulations. The letter was issued by the FDA's drug regulatory division, though the specific issuing office is not identified in the available metadata. Further review of the complete Warning Letter would be necessary to determine the exact nature and scope of the compliance failures cited.